Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03348904 · ClinicalTrials.gov registry record · Phase 3
Nivolumab and Epacadostat With Platinum Doublet Chemotherapy Versus Platinum Doublet Chemotherapy in Non-Small Cell Lung Cancer
A Phase 3 study, sponsored by Incyte Corporation.
- Terminated
- Registry status
- Phase 3
- Development phase
- 2
- Enrollment target
NCT03348904: Clinical Trial Phase 3 study, sponsored by Incyte Corporation.
NCT03348904 is a Phase 3 study that was terminated before completion, run by Incyte Corporation. The registered enrollment target is 2 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (100% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03348904, a Phase 3 study, was terminated before completion, sponsored by Incyte Corporation.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 2 participants
- Enrollment target
Study Summary
The purpose of this study was to evaluate the efficacy and safety of the combination of nivolumab plus epacadostat in combination with platinum chemotherapy compared with platinum chemotherapy alone, in participants with treatment-naïve Stage 4 or recurrent non-small cell lung cancer (NSCLC).
Primary Outcome
Defined as the time from randomization to the date of death from any cause.
Interventions
- DRUG Carboplatin
- DRUG Placebo
- DRUG Cisplatin
- DRUG Epacadostat
- DRUG Nivolumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2017-12-27 |
| Est. Completion | 2018-05-22 |
| Phase | Phase 3 |
Why NCT03348904 stopped before completion
NCT03348904 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 2 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (100% lower).
The record links to 0 conditions, and to 5 interventions - of which Carboplatin is the first listed.
NCT03348904 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03348904 about?
NCT03348904 is a clinical study titled "Nivolumab and Epacadostat With Platinum Doublet Chemotherapy Versus Platinum Doublet Chemotherapy in Non-Small Cell Lung Cancer". The purpose of this study was to evaluate the efficacy and safety of the combination of nivolumab plus epacadostat in combination with platinum chemotherapy compared with platinum chemotherapy alone, in participants with treatment-naïve Stage 4 or recurrent non-small cell lung cancer (NSCLC).
What is the current status of trial NCT03348904?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 2 participants. The study started on 2017-12-27. Estimated completion is 2018-05-22.
What interventions are being tested in trial NCT03348904?
The interventions under investigation include: Carboplatin (DRUG), Placebo (DRUG), Cisplatin (DRUG), Epacadostat (DRUG), Nivolumab (DRUG).
Who is sponsoring clinical trial NCT03348904?
This trial is sponsored by Incyte Corporation, which has 239 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03348904's enrollment target sits among peer trials
2 2000th of 2000 the lowest of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI